🇺🇸 FDA

Intelligence · Clinical Pipeline

Acadia Pharmaceuticals Pipeline

All ClinicalTrials.gov programs at Acadia Pharmaceuticals — phase, modality, and trial IDs.

Programs
32

Quick answer

Acadia Pharmaceuticals has 32 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. ACP-204

    Acadia Pharmaceuticals B.V.

    Lewy Body Dementia Psychosis

    phase 3 small molecule active

    2 trials

  2. ACP-204

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 3 small molecule active

    2 trials

  3. Carbetocin

    Acadia Pharmaceuticals B.V.

    Hyperphagia in Prader-Willi Syndrome

    phase 3 small molecule active

    2 trials

  4. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    phase 3 small molecule completed

    2 trials

  5. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Adjunctive Treatment of Major Depressive Disorder

    phase 3 small molecule terminated

    3 trials

  6. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 3 small molecule completed

    4 trials

  7. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Irritability Associated With Autism Spectrum Disorder

    phase 3 small molecule completed

    2 trials

  8. Pimavanserin tartrate (ACP-103)

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    4 trials

  9. Placebo

    Acadia Pharmaceuticals B.V.

    Dementia-related Psychosis

    phase 3 small molecule completed

    1 trial

  10. Trofinetide

    Acadia Pharmaceuticals B.V.

    Rett Syndrome

    phase 3 small molecule completed

    4 trials

  11. pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    1 trial

  12. ACP-044 Dose A

    Acadia Pharmaceuticals B.V.

    Acute Postoperative Pain

    phase 2 small molecule completed

    1 trial

  13. ACP-044 Dose A

    Acadia Pharmaceuticals B.V.

    Osteoarthritis Pain

    phase 2 small molecule terminated

    1 trial

  14. ACP-103

    Acadia Pharmaceuticals B.V.

    Hallucinations

    phase 2 small molecule completed

    1 trial

  15. ACP-103

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  16. ACP-104

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  17. ACP-211

    Acadia Pharmaceuticals B.V.

    Major Depressive Disorder (MDD)

    phase 2 small molecule active

    1 trial

  18. Active drug: pimavanserin 17mg (2 strength tablets)

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  19. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  20. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  21. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Treatment of Depression in Adults With Parkinson's Disease (PD)

    phase 2 small molecule completed

    1 trial

  22. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  23. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Intermittent Explosive Disorder

    phase 2 small molecule active

    1 trial

  24. Pimavanserin 34 milligrams (MG) [Nuplazid]

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  25. Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]

    Acadia Pharmaceuticals B.V.

    Autism Spectrum Disorder

    phase 2 small molecule active

    1 trial

  26. Pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 2 small molecule completed

    1 trial

  27. Placebo

    Acadia Pharmaceuticals B.V.

    Anxiety

    phase 2 small molecule active

    1 trial

  28. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 1 small molecule terminated

    1 trial

  29. L. helveticus R0052 and B. longum R0175

    Acadia Pharmaceuticals B.V.

    Attention Deficit Hyperactivity Disorder

    approved other active

    1 trial

  30. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Neurodegenerative Diseases

    approved small molecule active

    1 trial

  31. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Insomnia Chronic

    approved small molecule terminated

    1 trial

  32. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson Disease Psychosis

    approved small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Acadia Pharmaceuticals have?

32 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.